Latest Chemomab Therapeutics News & Updates

See the latest news and media coverage for Chemomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Chemomab Therapeutics (Chemomab)

Clinical-stage biotechnology company developing fibro-inflammatory therapeutics

chemomab.com
Headquarters
Tel Aviv, Israel
Founded year
2011
Company type
Public company
Number of employees
20–50

Last updated

Latest news about Chemomab Therapeutics (Chemomab)

In short: Chemomab advanced its lead candidate nebokitug toward a Phase 3 trial for PSC following positive Phase 2 results and alignment with the FDA.

Company announcements

  • Chemomab

    Chemomab announces nebokitug proteomic study results

    Dr. Parvez Mantry presented dose-dependent reductions in inflammatory signatures at Digestive Disease Week. Data suggest benefits for PSC patients with IBD. Q1 2026 results release on May 14.

  • Chemomab

    Chemomab announces 2025 year-end financial results

    Reports $10.4M cash, reduced R&D expenses, net loss of $9.0M. Highlights FDA alignment on Phase 3 PSC trial for nebokitug and strategic partner discussions.

  • Chemomab

    Chemomab develops treatments for rare diseases

    Nebokitug prepares for Phase 3 trial in primary sclerosing cholangitis and is Phase 2-ready for systemic sclerosis.

  • Chemomab

    Chemomab announces publication of nebokitug Phase 2 trial results

    SPRING trial data show nebokitug is safe, well-tolerated, and improves fibrosis and inflammation biomarkers in PSC patients, especially moderate/advanced fibrosis subgroup. Supports Phase 3 trial.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Chemomab

Track Chemomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Chemomab competitors & trending companies

Browse news for competitors to Chemomab and other trending companies.